INTERPRETATION: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.